Help
RSS
API
Feed
Maltego
Contact
Domain > www.rayaldee.eu
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2024-09-19
54.92.246.172
(
ClassC
)
2025-11-02
52.20.218.66
(
ClassC
)
2025-11-10
52.21.242.136
(
ClassC
)
2025-11-20
44.193.150.60
(
ClassC
)
Port 80
HTTP/1.1 200 OKDate: Sun, 02 Nov 2025 16:23:56 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: keep-aliveServer: Cache-Control: max-age86400, publicContent-language: enX- !DOCTYPE html>html langen dirltr prefixcontent: http://purl.org/rss/1.0/modules/content/ dc: http://purl.org/dc/terms/ foaf: http://xmlns.com/foaf/0.1/ og: http://ogp.me/ns# rdfs: http://www.w3.org/2000/01/rdf-schema# schema: http://schema.org/ sioc: http://rdfs.org/sioc/ns# sioct: http://rdfs.org/sioc/types# skos: http://www.w3.org/2004/02/skos/core# xsd: http://www.w3.org/2001/XMLSchema# >head> meta charsetutf-8 />meta namedescription contentWhere licensed, Rayaldee® is indicated for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease stage 3 or 4 and vitamin D insufficiency or deficiency. />link relcanonical hrefhttps://www.rayaldee.eu/ />link relshortlink hrefhttps://www.rayaldee.eu/ />meta propertyog:site_name contentRayaldee />meta propertyog:url contenthttps://www.rayaldee.eu/node />meta propertyog:image contenthttps://www.rayaldee.eu/themes/custom/rayaldee_v2/img/home-page-information-background-v2.jpg />meta propertyog:image:url contenthttps://www.rayaldee.eu/themes/custom/rayaldee_v2/img/home-page-information-background-v2.jpg />link relapple-touch-icon sizes180x180 hrefhttps://www.rayaldee.eu/themes/custom/rayaldee_v2/src/img/favicons/apple-touch-icon.png />link relicon typeimage/png sizes32x32 hrefhttps://www.rayaldee.eu/themes/custom/rayaldee_v2/src/img/favicons/favicon-32x32.png />link relicon sizes16x16 hrefhttps://www.rayaldee.eu/themes/custom/rayaldee_v2/src/img/favicons/favicon-16x16.png />link relmask-icon hrefhttps://www.rayaldee.eu/themes/custom/rayaldee_v2/src/img/favicons/safari-pinned-tab.svg color#5bbad5 />meta namemsapplication-TileColor content#da532c />meta nameMobileOptimized contentwidth />meta nameHandheldFriendly contenttrue />meta nameviewport contentwidthdevice-width, initial-scale1.0 />script srchttps://cdn.cookielaw.org/scripttemplates/otSDKStub.js data-document-languagetrue typetext/javascript charsetUTF-8 data-domain-scriptcdd3d1b8-779c-4e87-bba7-44c980d186fa>/script>script typetext/javascript> function OptanonWrapper() { }/script>l
Port 443
HTTP/1.1 200 OKDate: Sun, 02 Nov 2025 16:23:56 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: keep-aliveServer: Cache-Control: max-age86400, publicContent-language: enX- !DOCTYPE html>html langen dirltr prefixcontent: http://purl.org/rss/1.0/modules/content/ dc: http://purl.org/dc/terms/ foaf: http://xmlns.com/foaf/0.1/ og: http://ogp.me/ns# rdfs: http://www.w3.org/2000/01/rdf-schema# schema: http://schema.org/ sioc: http://rdfs.org/sioc/ns# sioct: http://rdfs.org/sioc/types# skos: http://www.w3.org/2004/02/skos/core# xsd: http://www.w3.org/2001/XMLSchema# >head> meta charsetutf-8 />meta namedescription contentWhere licensed, Rayaldee® is indicated for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease stage 3 or 4 and vitamin D insufficiency or deficiency. />link relcanonical hrefhttps://www.rayaldee.eu/ />link relshortlink hrefhttps://www.rayaldee.eu/ />meta propertyog:site_name contentRayaldee />meta propertyog:url contenthttps://www.rayaldee.eu/node />meta propertyog:image contenthttps://www.rayaldee.eu/themes/custom/rayaldee_v2/img/home-page-information-background-v2.jpg />meta propertyog:image:url contenthttps://www.rayaldee.eu/themes/custom/rayaldee_v2/img/home-page-information-background-v2.jpg />link relapple-touch-icon sizes180x180 hrefhttps://www.rayaldee.eu/themes/custom/rayaldee_v2/src/img/favicons/apple-touch-icon.png />link relicon typeimage/png sizes32x32 hrefhttps://www.rayaldee.eu/themes/custom/rayaldee_v2/src/img/favicons/favicon-32x32.png />link relicon sizes16x16 hrefhttps://www.rayaldee.eu/themes/custom/rayaldee_v2/src/img/favicons/favicon-16x16.png />link relmask-icon hrefhttps://www.rayaldee.eu/themes/custom/rayaldee_v2/src/img/favicons/safari-pinned-tab.svg color#5bbad5 />meta namemsapplication-TileColor content#da532c />meta nameMobileOptimized contentwidth />meta nameHandheldFriendly contenttrue />meta nameviewport contentwidthdevice-width, initial-scale1.0 />script srchttps://cdn.cookielaw.org/scripttemplates/otSDKStub.js data-document-languagetrue typetext/javascript charsetUTF-8 data-domain-scriptcdd3d1b8-779c-4e87-bba7-44c980d186fa>/script>script typetext/javascript> function OptanonWrapper() { }/script>l
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]